Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Alnylam identifies new method to monitor RNAi activity
March 2012
SHARING OPTIONS:

CAMBRIDGE, Mass.A novel method of monitoring RNAi activity in blood samples has been discovered by Alnylam Pharmaceuticals Inc., providing the potential for advances in the development of RNAi therapeutics and diagnostics. The new method, circulating extracellular RNA detection (cERD), allows for the quantitative measurement of tissue-specific mRNA silencing from biological fluids, including blood and cerebrospinal fluid. Preclinical results demonstrate the new method's ability to quantitatively monitor tissue-specific mRNA modulation in a non-invasive manner, particularly in blood and cerebrospinal fluid. The cERD method enables analysis of all circulating RNA. Alnylam plans to support academic research and industry efforts in RNAi therapeutics with the cERD method by way of a broad-based licensing effort, and the first license for the method has been provided to Isis Pharmaceuticals.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.